Lentivirus vector plasmid of human SOX2 for generating iPS cells.
| Clone info. | Lentivirus vector plasmid of human SOX2 for generating iPS cells. |
|---|---|
| Comment | pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394) are popular choices for lentivirus packaging. |
| Vector backbone | CSIV-CMV-RfA-IRES2-Venus (Plasmid) |
| Selectable markers | Ampicillin (E. coli). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector. |
| Gene/insert name | Human SOX2 cDNA |
| Depositor|Developer | Miyoshi, Hiroyuki | |
| Sequence | RDB08324z.seq |
|---|---|
| Remarks, protocol and/or map (pdf) | RDB08324.pdf |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment MTA, for use for not-for-profit academic purpose [Word Please visit Ordering instruction.[link] |
|---|---|
| Terms and conditions for distribution | The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe the late Dr. Hiroyuki Miyoshi as the Developer. Additional terms and conditions: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). |
| Remarks | ((Remarks)) Remember that you will be working with samples containing infectious virus. Please contact us. We will provide you with appropriate documents. Gateway® Expression clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC. |
[open/close]| 必要書類 | 提供依頼書 提供同意書 (MTA, 非営利学術目的用)[Word 手続きの概要は、「レンチウイルスベクターの提供申し込み」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が故三好浩之博士により開発されたことを明示する。 付加的使用条件: When publishing the results obtained using the BIOLOGICAL RESOURCE, a citation of literature specified by Dr. Atsushi Miyawaki or an acknowledgement to Dr. Miyawaki is requested. Nagai, T. et al., Nat. Biotechnol. 20: 87-90 (2002). |
| 備考 | 【使用上の注意】このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。 Gateway®テクノロジーを用いた発現クローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。 |
| Catalog # | Resource name | Availability | Shipping form | Fee |
|---|---|---|---|---|
| RDB08324 | CSIV-CMV-hSox2-IRES2-Venus | Under QC test. Please contact us. | DNA solution |
JPY 9,460 (not-for-profit academic purpose) plus cost of shipping containers, dry ice (if required) and shipping charge plus licensing fee equivalent for Gateway® expression clone |
Materials & Methods section:
| The CSIV-CMV-hSox2-IRES2-Venus was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB08324). |
Reference section:
Further references such as user reports and related articles (go to bottom)
Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.
Original, user report and related articles
Featured content